Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence.
Nugteren S, den Uil SH, Delis-van Diemen PM, Simons-Oosterhuis Y, Lindenbergh-Kortleve DJ, van Haaften DH, Stockmann HBAC, Sanders J, Meijer GA, Fijneman RJA, Samsom JN. Nugteren S, et al. Among authors: sanders j. Sci Rep. 2022 Jul 16;12(1):12174. doi: 10.1038/s41598-022-16427-5. Sci Rep. 2022. PMID: 35842496 Free PMC article.
Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression.
Komor MA, de Wit M, van den Berg J, Martens de Kemp SR, Delis-van Diemen PM, Bolijn AS, Tijssen M, Schelfhorst T, Piersma SR, Chiasserini D, Sanders J, Rausch C, Hoogstrate Y, Stubbs AP, de Jong M, Jenster G, Carvalho B, Meijer GA, Jimenez CR, Fijneman RJA; NGS-ProToCol Consortium. Komor MA, et al. Among authors: sanders j. Int J Cancer. 2020 Apr 1;146(7):1979-1992. doi: 10.1002/ijc.32627. Epub 2019 Aug 30. Int J Cancer. 2020. PMID: 31411736 Free PMC article.
Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis.
Nugteren S, Goos JACM, Delis-van Diemen PM, Simons-Oosterhuis Y, Lindenbergh-Kortleve DJ, van Haaften DH, Sanders J, Meijer GA, Fijneman RJA, Samsom JN. Nugteren S, et al. Among authors: sanders j. Oncoimmunology. 2020 Oct 13;9(1):1832761. doi: 10.1080/2162402X.2020.1832761. Oncoimmunology. 2020. PMID: 33101778 Free PMC article.
Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
den Uil SH, de Wit M, Slebos RJC, Delis-van Diemen PM, Sanders J, Piersma SR, Pham TV, Coupé VMH, Bril H, Stockmann HBAC, Jimenez CR, Meijer GA, Fijneman RJA. den Uil SH, et al. Among authors: sanders j. Eur J Cancer. 2021 Feb;144:91-100. doi: 10.1016/j.ejca.2020.10.029. Epub 2020 Dec 17. Eur J Cancer. 2021. PMID: 33341450 Free article.
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†.
van Rhijn BWG, Mertens LS, Mayr R, Bostrom PJ, Real FX, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, van der Heijden MS, Jewett MAS, Marquez M, Stoehr R, Zlotta AR, Eckstein M, Soorojebally Y, Roshani H, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, Wullich B, van der Kwast TH, Malats N, Hartmann A, Allory Y, Zuiverloon TCM. van Rhijn BWG, et al. Among authors: sanders j. Eur Urol. 2020 Nov;78(5):682-687. doi: 10.1016/j.eururo.2020.07.002. Epub 2020 Jul 15. Eur Urol. 2020. PMID: 32682615
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.
Versluis JM, Blankenstein SA, Dimitriadis P, Wilmott JS, Elens R, Blokx WAM, van Houdt W, Menzies AM, Schrage YM, Wouters MWJM, Sanders J, Broeks A, Scolyer RA, Suijkerbuijk KPM, Long GV, Akkooi ACJV, Blank CU. Versluis JM, et al. Among authors: sanders j. J Immunother Cancer. 2024 Apr 27;12(4):e008125. doi: 10.1136/jitc-2023-008125. J Immunother Cancer. 2024. PMID: 38677880 Free PMC article.
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Sobral-Leite M, Salomon I, Opdam M, Kruger DT, Beelen KJ, van der Noort V, van Vlierberghe RLP, Blok EJ, Giardiello D, Sanders J, Van de Vijver K, Horlings HM, Kuppen PJK, Linn SC, Schmidt MK, Kok M. Sobral-Leite M, et al. Among authors: sanders j. Breast Cancer Res. 2019 Aug 7;21(1):90. doi: 10.1186/s13058-019-1176-2. Breast Cancer Res. 2019. PMID: 31391067 Free PMC article.
3,446 results